U.S. press attentionCheck this out...google.....nasd100.com. Canadian stock ranking This was released Jan 10/10. Of the stocks ranked BNC was #11 of 500 / strong buy. Our American friends can not only play the growth but also the fx as the flavor of the year is still a deterioration of the U.S. dollar. So they can buy at a discount and if the buck falls over the year possibly sell for a premium if the Can. buck is at parity or above. Could be a 15 t0 25% gain even if the stock price doesn't move. A tiny U.S.$50.K would have bought over 100k shares a few weeks back. I would think this would be of interest to those who follow Endo and perhaps have some better contacts.
I was intrigued by our future milestones in earlier posts. It is my opinion that while these are important and will create share value the most imminent and pressing is Endo's release that the 2cd phase 3 trial has begun..If Endo commits to this trial we are almost guaranteed that the first p3 trial at least met its end points. They will not commit the time and $ until they are sure that there is some potential that it can be successfully commercialized. They will not negotiate global rights if they have not started their p3b trial. I don't think we will get any more payments either until trial 3a results are out....and then only if we meet end points. If and when Endo begins its final p3 trial it not only gives credibility to Urocidin but pushes the whole MCC platform up a huge step for the treatment of many other cancers. As I said before I believe this will happen soon as a good percentage of the p3a results have been compiled. My original position remains but I will wait the p3b release for my next investment although greatly encouraged by the last week. Many years and still waiting...Dusty11